Hypertension and Dyslipidemia
15
0
0
15
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (15)
A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348
Study to Evaluate the Safety and Pharmacokinetics of CKD-331
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386
A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348
Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers